Assessment of the occurrence and factors influencing hepatitis B, hepatitis C, and liver damage in individuals with HIV undergoing antiretroviral treatment in Ghana's Upper East Region - Scorecard - MDSpire
Advertisement
Assessment of the occurrence and factors influencing hepatitis B, hepatitis C, and liver damage in individuals with HIV undergoing antiretroviral treatment in Ghana's Upper East Region
Clinical Scorecard: Assessment of the occurrence and factors influencing hepatitis B, hepatitis C, and liver damage in individuals with HIV undergoing antiretroviral treatment in Ghana's Upper East Region
At a Glance
Category
Detail
Condition
HIV co-infection with Hepatitis B and C
Key Mechanisms
Overlap in transmission routes and ART-related hepatotoxicity
Target Population
People living with HIV (PLHIV) in Ghana's Upper East Region
Care Setting
ART clinics in Bongo District Hospital, Paga District Hospital, and War Memorial Hospital
Key Highlights
High prevalence of HBV (15.6%) and HCV (8.4%) among PLHIV in the Upper East Region
Co-infection complicates ART decisions and accelerates liver injury
Routine screening for HBV and HCV is not universally implemented
Tenofovir-based regimens are preferred for HBV co-infected patients
Direct-acting antivirals (DAAs) are effective for HIV-HCV co-infection management
Guideline-Based Recommendations
Diagnosis
Routine screening for HBV and HCV in PLHIV is recommended
Management
Use tenofovir-based regimens for HBV co-infected patients
Avoid hepatotoxic agents in patients with advanced liver disease
Monitoring & Follow-up
Regular monitoring of liver enzymes and hepatic function in co-infected patients
Risks
Increased risk of liver injury due to ART and co-morbidities
Patient & Prescribing Data
PLHIV receiving ART in Ghana's Upper East Region
Careful selection of ART regimens is crucial to minimize hepatotoxicity
Clinical Best Practices
Implement routine HBV and HCV screening in ART clinics
Educate healthcare providers on the management of co-infected patients
Ensure access to DAAs for HCV treatment in resource-limited settings
by Francis Yennube Duut, Samuel Punignan Nfoke, Elvis Ayamga, Naja Kwayaja, Dodzi Kwaku Jnr Senoo, Godfred Agongo, James Abugri, Sylvester Donne Dassah
